[go: up one dir, main page]

BR9909350A - Compostos, composição, utilização de um composto, e, processos para preparação dos compostos, para transferência de ácido nucleicos para as células e para tratamento de doenças por meio de administração de um ácido nucleico - Google Patents

Compostos, composição, utilização de um composto, e, processos para preparação dos compostos, para transferência de ácido nucleicos para as células e para tratamento de doenças por meio de administração de um ácido nucleico

Info

Publication number
BR9909350A
BR9909350A BR9909350-2A BR9909350A BR9909350A BR 9909350 A BR9909350 A BR 9909350A BR 9909350 A BR9909350 A BR 9909350A BR 9909350 A BR9909350 A BR 9909350A
Authority
BR
Brazil
Prior art keywords
compounds
nucleic acids
cells
processes
compound
Prior art date
Application number
BR9909350-2A
Other languages
English (en)
Inventor
Gerardo Byk
Daniel Schermann
Marc Frederic
Hans Hofland
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9804121A external-priority patent/FR2777017B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BR9909350A publication Critical patent/BR9909350A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

"COMPOSTOS, COMPOSIçãO, UTILIZAçãO DE UM COMPOSTO, E, PROCESSOS PARA PREPARAçãO DOS COMPOSTOS, PARA TRANSFERêNCIA DE áCIDOS NUCLEICOS PARA AS CéLULAS E PARA TRATAMENTO DE DOENçAS POR MEIO DE ADMINISTRAçãO DE UM áCIDO NUCLEICO". A presente invenção refere-se a novos compostos úteis como agentes de transferência de ácidos nucleicos nas células. Estes novos compostos são relacionados, mais particularmente, com a família das lipopoliaminas, e comportam pelo menos uma função amidina cíclica. Eles são úteis para a transfecção dos ácidos nucleicos de interesse em diferentes tipos celulares, tanto in vitro como in vivo ou ex vivo.
BR9909350-2A 1998-04-02 1999-03-30 Compostos, composição, utilização de um composto, e, processos para preparação dos compostos, para transferência de ácido nucleicos para as células e para tratamento de doenças por meio de administração de um ácido nucleico BR9909350A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9804121A FR2777017B1 (fr) 1998-04-02 1998-04-02 Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications
US8584598P 1998-05-18 1998-05-18
PCT/FR1999/000740 WO1999051581A1 (fr) 1998-04-02 1999-03-30 Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications

Publications (1)

Publication Number Publication Date
BR9909350A true BR9909350A (pt) 2000-12-12

Family

ID=26234240

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909350-2A BR9909350A (pt) 1998-04-02 1999-03-30 Compostos, composição, utilização de um composto, e, processos para preparação dos compostos, para transferência de ácido nucleicos para as células e para tratamento de doenças por meio de administração de um ácido nucleico

Country Status (12)

Country Link
EP (1) EP1068188A1 (pt)
JP (1) JP2002513543A (pt)
KR (1) KR20010042318A (pt)
CN (1) CN1294582A (pt)
AU (1) AU759301B2 (pt)
BR (1) BR9909350A (pt)
CA (1) CA2324931A1 (pt)
HU (1) HUP0102455A3 (pt)
IL (1) IL138625A0 (pt)
NO (1) NO317225B1 (pt)
PL (1) PL342886A1 (pt)
WO (1) WO1999051581A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091242A1 (en) 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
ITMI20050222A1 (it) * 2005-02-15 2006-08-16 Milano Politecnico Lipidi cationici per la trasfezione di acidi nucleici

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2714830B1 (fr) * 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) * 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2741066B1 (fr) * 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
ATE198599T1 (de) * 1996-03-01 2001-01-15 Centre Nat Rech Scient Guanidinium-verbindungen, pharmazeutische präparate davon und ihre verwendungen

Also Published As

Publication number Publication date
PL342886A1 (en) 2001-07-16
EP1068188A1 (fr) 2001-01-17
WO1999051581A1 (fr) 1999-10-14
JP2002513543A (ja) 2002-05-14
HUP0102455A3 (en) 2003-09-29
CA2324931A1 (fr) 1999-10-14
IL138625A0 (en) 2001-10-31
AU3406100A (en) 2000-11-30
NO317225B1 (no) 2004-09-20
CN1294582A (zh) 2001-05-09
AU759301B2 (en) 2003-04-10
KR20010042318A (ko) 2001-05-25
NO20004780L (no) 2000-11-01
NO20004780D0 (no) 2000-09-25
HUP0102455A2 (hu) 2001-10-28

Similar Documents

Publication Publication Date Title
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
ES2156421T3 (es) Composiciones utiles para la transferencia de polinucleotidos terapeuticamente activos a una celula diana y su utilizacion en la terapia genica.
ATE13286T1 (de) Pharmazeutisch aktive phenylcarbonsaeurederivate.
MX9706380A (es) Guanidinas de acidos alquenil-carboxilicos sustituidos con fenilo, procedimientos para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como un medicamento que las contiene.
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
NO962791L (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
ATE313642T1 (de) Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung
NO20010531L (no) Medisinske aerosolformuleringer
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
EE9700146A (et) Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine
EP0221041A3 (en) Benzimidazole derivatives, process for their preparation and their pharmaceutical use
DE3267039D1 (en) Stable s-adenosylmethionine salts, the process for their preparation and therapeutic compositions which contain them as active principle
BR0007360A (pt) Composição de liberação controlada
TR200103153T2 (tr) Yeni bileşimler
BR9807319A (pt) Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos.
EP0271795A3 (de) Octahydro-10-oxo-6H-pyridazo [1,2-a] [1,2] diazepin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel
AR008387A1 (es) Nuevas 5-fenoxialquil-tiazolidin-2,4-dionas, procedimientos para obtenerlas, nuevos compuestos intermedios de estos procedimientos ycomposiciones farmaceuticas que contienen las nuevas 5-fenoxialquil-tiazolidin- 2,4-dionas
BR0016133A (pt) Composto, formulação farmacêutica, e, uso de um composto
MXPA06000243A (es) Formulacion farmaceutica liofilizada estable de tetrodotoxina.
BR0016130A (pt) Composto, formulação farmacêutica, e, uso de um composto
BRPI0407907A (pt) derivados de ácido alcánico substituìdos com aril-cicloaquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1945 DE 15 - 04 - 2008.